Low level of antioxidant capacity biomarkers but not target overexpression predicts vulnerability to ROS-inducing drugs

Abstract
Despite a strong rationale for why cancer cells are susceptible to redox-targeting drugs, such drugs often face tumor resistance or dose-limiting toxicity in preclinical and clinical studies. An important reason is the lack of specific biomarkers to better select susceptible cancer entities and stratify patients. Using a large panel of lung cancer cell lines, we identified a set of “antioxidant-capacity” biomarkers (ACB), which were tightly repressed, partly by STAT3 and STAT5A/B in sensitive cells, rendering them susceptible to multiple redox-targeting and ferroptosis-inducing drugs. Contrary to expectation, constitutively low ACB expression was not associated with an increased steady state level of reactive oxygen species (ROS) but a high level of nitric oxide, which is required to sustain high replication rates. Using ACBs, we identified cancer entities with a high percentage of patients with favorable ACB expression pattern, making it likely that more responders to ROS-inducing drugs could be stratified for clinical trials.
Competing Interest Statement
The authors have declared no competing interest.
Subject Area
- Biochemistry (13850)
- Bioengineering (10540)
- Bioinformatics (33486)
- Biophysics (17275)
- Cancer Biology (14344)
- Cell Biology (20317)
- Clinical Trials (138)
- Developmental Biology (10963)
- Ecology (16159)
- Epidemiology (2067)
- Evolutionary Biology (20489)
- Genetics (13496)
- Genomics (18776)
- Immunology (13897)
- Microbiology (32437)
- Molecular Biology (13508)
- Neuroscience (70740)
- Paleontology (532)
- Pathology (2219)
- Pharmacology and Toxicology (3770)
- Physiology (5942)
- Plant Biology (12117)
- Synthetic Biology (3400)
- Systems Biology (8222)
- Zoology (1860)